News
Atlantic Cancer Research Institute and Université de Moncton strengthening New Brunswick’s bioscience sector
April 18, 2019 – Moncton, NB – Atlantic Canada Opportunities Agency
Developing new technology and seeking healthcare innovations to offer Canadians better access to medical treatment are key to improving lives, advancing standards of care and encouraging prosperity.
Moncton-based Atlantic Cancer Research Institute (ACRI) and the Université de Moncton (U de M) are undertaking projects to bring cutting-edge disease screening technology and research platforms one step closer to commercialization, and to establish the New Brunswick Centre for Precision Medicine (NBCPM).
The Government of Canada, through the Atlantic Canada Opportunities Agency (ACOA), is providing non-repayable contributions totalling more than $4.9 million for these projects, while the New Brunswick Innovation Foundation (NBIF) is contributing $374,000 to the U de M project.
The Honourable Ginette Petitpas Taylor, Minister of Health and Member of Parliament for Moncton-Riverview-Dieppe, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA, along with the Honourable Dominic LeBlanc, Minister of Intergovernmental and Northern Affairs and Internal Trade and Member of Parliament for Beauséjour, ACRI officials, and U de M representatives made the announcement today.
Economic growth and the creation of good jobs for Atlantic Canadians require innovation and diversification. Support for these projects is one way the Government of Canada is growing the innovation economy by working to sustain strategic clusters, and enhance the development and reach of business accelerators and incubators. Projects like these also contribute to the Atlantic Growth Strategy outcome of long-term economic prosperity in the region.
ST. JOHN’S, N.L. (FRIDAY, APRIL 12TH, 2019) – For the first time, leading cancer centres, hospitals and researchers in Atlantic Canada are coming together to help deliver personalized and precision medicine to cancer patients across the region.
The group, known as the Atlantic Cancer Consortium (ACC), is comprised of about 40 researchers and clinicians from institutions in New Brunswick, Nova Scotia and Newfoundland and Labrador and hopes to join the Marathon of Hope Cancer Centres Network, a national initiative launched today by the Terry Fox Research Institute (TFRI) in St. John’s, N.L.
Representatives from the three provinces participated in the launch event in St. John’s. The consortium will make an application to the national network next month for funding to launch a pilot project focused on colorectal and lung cancers, the two most prevalent cancers in the region.
On October 19th, during a “Prostate Cancer Wakeup Call”, the Prostate Cancer Foundation has raised a total of $61,530. A portion of this amount will benefit the Atlantic Cancer Research Institute. We would like to thank all the people involved with this event and also all the people that were present during this fundraiser for prostate cancer research.
(Moncton, NB) September 13th, 2018 - On September 13th, during a golf tournament at the Fox Creek Golf Club, the National Bank, their employees and their sponsors have raised $25000 dollars to benefit the Atlantic Cancer Research Institute. We would also like to thank Stéphane Achard, Executive Vice President of Commercial Banking & Insurance at the National Bank, for an additional donation of $10000 dollars for a grand total of $35000 dollars.
ACRI would like to thank the National Bank and all those involved for their generous support.
( Moncton, NB )- August 10th, 2018 -Yesterday, during a golf tournament to benefit the Atlantic Cancer Research Institute (ACRI), Assumption Life, their employees and their sponsors have raised fifty thousand dollars.
ACRI would like to thank Assumption-Life and all those involved for their generous support.
( Moncton, NB )- July 27, 2018 - Yesterday, we had the pleasure of welcoming the New Brunswick Minister of Health, Mr. Benoît Bourque, at the Atlantic Cancer Research Institute (ACRI). Dr. Jocelyn Paré gave him a tour of our research laboratories and presented him with details about the activity he leads at ACRI, namely an ablation technology that combines the advantages of chemical ablation to those of microwave ablation.
(Moncton, NB) - June 7th, 2018 - Dooly's franchisees, their employees and customers have officially raised a grand total of $1 million over the last 13 years in support of the Atlantic Cancer Research Institute (ACRI). ACRI would like to thank Dooly's and all those involved for their generous support over the years and for reaching this great achievement.
For information on how you could support the Atlantic Cancer Research Institute, please contact
Remi Richard
Business Development Officer
Phone : +1 506 869 2048
Fax : +1 506 862 7571
Moncton, New Brunswick -- (January 9, 2018) - Atlantic Cancer Research Institute is pleased to announce the European Patent Office (EPO) has granted as of December 27, 2017 Patent Application No. 2688904 entitled: POLYPEPTIDES WITH AFFINITY FOR HEAT SHOCK PROTEINS (HSPS) AND HSP ASSOCIATED COMPLEXES (HACS) AND THEIR USE IN DIAGNOSIS AND THERAPY.
ACRI also holds a granted patent for this technology in the United States (US Patent # 8,956,878). ACRI's technology described in the patent includes the Vn96 peptide used for liquid biopsy applications. The peptide has a high affinity for heat shock proteins (HSPs) lining the surface extracellular vesicles (EVs). EVs contain a sample of the DNA, RNA, protein and metabolites found within the cells from which they are derived. Since EVs appear in blood, urine and other body fluids, they are a rich biomarker source that can be obtained by minimally-invasive methods to screen for diseases.
The ACRI team is working to identify the specific proteins and nucleic acids that are released from cancer cells in these small biomarker packets. These cancer-specific proteins and nucleic acids hold the potential to be used as new biomarkers for cancer detection using a liquid biopsy. ACRI is focused on advancing its extracellular vesicle capture technologies to enable new cancer diagnostic, prognostic, and treatment-response tests.
For technology information, collaborations or partnerships, please contact:
Remi Richard
Business Development Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone : +1 506 869 2048
Fax : +1 506 862 7571
ACRI also holds a granted patent for this technology in the United States (US Patent # 8,956,878). ACRI's technology described in the patent includes the Vn96 peptide used for liquid biopsy applications. The peptide has a high affinity for heat shock proteins (HSPs) lining the surface extracellular vesicles (EVs). EVs contain a sample of the DNA, RNA, protein and metabolites found within the cells from which they are derived. Since EVs appear in blood, urine and other body fluids, they are a rich biomarker source that can be obtained by minimally-invasive methods to screen for diseases.
The ACRI team is working to identify the specific proteins and nucleic acids that are released from cancer cells in these small biomarker packets. These cancer-specific proteins and nucleic acids hold the potential to be used as new biomarkers for cancer detection using a liquid biopsy. ACRI is focused on advancing its extracellular vesicle capture technologies to enable new cancer diagnostic, prognostic, and treatment-response tests.
For technology information, collaborations or partnerships, please contact:
Remi Richard
Business Development Officer
Phone : +1 506 869 2048
Fax : +1 506 862 7571
